The FDA’s upcoming June meeting plans to jab at a lineup of vaccines—COVID-19, RSV, flu, and even anthrax—but somehow skipped ...

RFK Jr.’s newly appointed CDC vaccine panel will not review HPV or meningitis vaccines but will vote on thimerosal, a ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

All 17 experts recently dismissed from a government vaccine advisory panel published an essay Monday decrying “destabilizing ...

GSK plc GSK announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to ...

The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...

The monoclonal antibody nirsevimab, though not a vaccine, is approved by the FDA for the prevention of RSV lower respiratory tract disease in newborns and infants born during or entering their ...

The FDA halted enrollment of young children in RSV vaccine trials after five infants in one study developed severe RSV infections. An FDA panel asked for additional data to better understand what ...

Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...

In July 2023, Moderna (MRNA) started an FDA process for real-time review of mRNA-1345 backed by late-stage data, which indicated a vaccine efficacy of 83.7% as defined by two or more RSV symptoms ...

Moderna's vaccine was approved by the FDA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 or older. The company had previously said its vaccine could be used ...

Abrysvo. The FDA approved Abrysvo for pregnant people to prevent RSV in infants from birth through 6 months of age. Expectant parents can get a single-dose shot of Abrysvo from 32 weeks through 36 ...